A citation-based method for searching scientific literature

Pasquale Pisapia, José Luis Costa, Francesco Pepe, Gianluca Russo, Gianluca Gragnano, Alessandro Russo, Antonino Iaccarino, Diego de Miguel-Perez, Maria Josè Serrano, Valeria Denninghoff, Luca Quagliata, Christian Rolfo, Umberto Malapelle. Crit Rev Oncol Hematol 2021
Times Cited: 6







List of co-cited articles
31 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
577
50

Liquid biopsy: monitoring cancer-genetics in the blood.
Emily Crowley, Federica Di Nicolantonio, Fotios Loupakis, Alberto Bardelli. Nat Rev Clin Oncol 2013
941
50

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.
Erika Rijavec, Simona Coco, Carlo Genova, Giovanni Rossi, Luca Longo, Francesco Grossi. Cancers (Basel) 2019
37
50

Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Nicolas Guibert, Anne Pradines, Gilles Favre, Julien Mazieres. Eur Respir Rev 2020
33
50

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Kye Young Lee,[...]. Lancet Oncol 2014
50

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Christian Rolfo, Philip Mack, Giorgio V Scagliotti, Charu Aggarwal, Maria E Arcila, Fabrice Barlesi, Trever Bivona, Maximilian Diehn, Caroline Dive, Rafal Dziadziuszko,[...]. J Thorac Oncol 2021
15
50

Liquid Biopsy and Lung Cancer.
Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone. Acta Cytol 2019
36
33

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, Paul Baas, Fabrice Barlesi, Trever G Bivona, Roy S Herbst, Tony S Mok, Nir Peled, Robert Pirker,[...]. J Thorac Oncol 2018
271
33

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Paula J Spitzler, Jonathon P Orme, M Raymond V Finlay, Richard A Ward, Martine J Mellor,[...]. Cancer Discov 2014
33

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Umberto Malapelle, Rafael Sirera, Eloísa Jantus-Lewintre, Pablo Reclusa, Silvia Calabuig-Fariñas, Ana Blasco, Pasquale Pisapia, Christian Rolfo, Carlos Camps. Expert Rev Mol Diagn 2017
79
33

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih-Hsin Yang, Ki Hyeong Lee, Shun Lu,[...]. Lancet Oncol 2016
601
33

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
33

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
33

Understanding EGFR heterogeneity in lung cancer.
Antonio Passaro, Umberto Malapelle, Marzia Del Re, Ilaria Attili, Alessandro Russo, Elena Guerini-Rocco, Caterina Fumagalli, Pasquale Pisapia, Francesco Pepe, Caterina De Luca,[...]. ESMO Open 2020
13
33

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
Cai-Hong Yun, Kristen E Mengwasser, Angela V Toms, Michele S Woo, Heidi Greulich, Kwok-Kin Wong, Matthew Meyerson, Michael J Eck. Proc Natl Acad Sci U S A 2008
33

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.
Mihaela Aldea, Lizza Hendriks, Laura Mezquita, Cécile Jovelet, David Planchard, Edouard Auclin, Jordi Remon, Karen Howarth, Jose Carlos Benitez, Anas Gazzah,[...]. J Thorac Oncol 2020
27
33

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
278
33

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).
Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, Luis Paz-Ares, Juan Jose Diaz Mochon, Ignacio Duran, Luis E Raez, Alessandro Russo, Jose A Lorente, Umberto Malapelle,[...]. Crit Rev Oncol Hematol 2020
31
33

Liquid biopsy tracking of lung tumor evolutions over time.
Alessandro Russo, Diego De Miguel Perez, Muthukumar Gunasekaran, Katherine Scilla, Rena Lapidus, Brandon Cooper, Ranee Mehra, Vincenzo Adamo, Umberto Malapelle, Christian Rolfo. Expert Rev Mol Diagn 2019
26
33

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Kenneth S Thress, Roz Brant, T Hedley Carr, Simon Dearden, Suzanne Jenkins, Helen Brown, Tracey Hammett, Mireille Cantarini, J Carl Barrett. Lung Cancer 2015
356
33

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
L Paz-Ares, E-H Tan, K O'Byrne, L Zhang, V Hirsh, M Boyer, J C-H Yang, T Mok, K H Lee, S Lu,[...]. Ann Oncol 2017
258
33

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
33

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
33

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
J-Y Douillard, G Ostoros, M Cobo, T Ciuleanu, R McCormack, A Webster, T Milenkova. Br J Cancer 2014
258
33

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
33

Detection of mutations in EGFR in circulating lung-cancer cells.
Shyamala Maheswaran, Lecia V Sequist, Sunitha Nagrath, Lindsey Ulkus, Brian Brannigan, Chey V Collura, Elizabeth Inserra, Sven Diederichs, A John Iafrate, Daphne W Bell,[...]. N Engl J Med 2008
33

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Natasha B Leighl, Ray D Page, Victoria M Raymond, Davey B Daniel, Stephen G Divers, Karen L Reckamp, Miguel A Villalona-Calero, Daniel Dix, Justin I Odegaard, Richard B Lanman,[...]. Clin Cancer Res 2019
175
33

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Shu Yi Shen, Rajat Singhania, Gordon Fehringer, Ankur Chakravarthy, Michael H A Roehrl, Dianne Chadwick, Philip C Zuzarte, Ayelet Borgida, Ting Ting Wang, Tiantian Li,[...]. Nature 2018
263
33

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Umberto Malapelle, Clara Mayo de-Las-Casas, Danilo Rocco, Monica Garzon, Pasquale Pisapia, Nuria Jordana-Ariza, Maria Russo, Roberta Sgariglia, Caterina De Luca, Francesco Pepe,[...]. Br J Cancer 2017
77
33

Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study.
Charles-Hugo Marquette, Jacques Boutros, Jonathan Benzaquen, Marion Ferreira, Jean Pastre, Christophe Pison, Bernard Padovani, Faiza Bettayeb, Vincent Fallet, Nicolas Guibert,[...]. Lancet Respir Med 2020
25
33

How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review.
Gabriel Fernando Torres, Carlos Eduardo Bonilla, Giancarlo Buitrago, Oscar Arrieta, Umberto Malapelle, Christian Rolfo, Andrés F Cardona. Crit Rev Oncol Hematol 2021
2
100

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Raffaella Sordella, Daphne W Bell, Daniel A Haber, Jeffrey Settleman. Science 2004
16

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
Paul A VanderLaan, Deepa Rangachari, Adnan Majid, Mihir S Parikh, Sidharta P Gangadharan, Michael S Kent, Danielle C McDonald, Mark S Huberman, Susumu S Kobayashi, Daniel B Costa. Lung Cancer 2018
31
16

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, Alessandra Ferro, Elisabetta Zulato, Ilaria Attili, Giorgia Nardo, Alessandro Dal Maso, Stefano Frega, Andrea Giovanni Menin,[...]. Transl Lung Cancer Res 2021
6
16


EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Susumu Kobayashi, Titus J Boggon, Tajhal Dayaram, Pasi A Jänne, Olivier Kocher, Matthew Meyerson, Bruce E Johnson, Michael J Eck, Daniel G Tenen, Balázs Halmos. N Engl J Med 2005
16

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, Stuart Horswell, M Math, James Larkin, David Endesfelder, Eva Gronroos, Pierre Martinez, Nicholas Matthews, Aengus Stewart,[...]. N Engl J Med 2012
16

The Promising Evolution of Targeted Therapeutic Strategies in Cancer.
Solange Peters, Tony Mok, Antonio Passaro, Pasi Antero Jänne. Cancer Discov 2021
3
33

Molecular profiling for precision cancer therapies.
Eoghan R Malone, Marc Oliva, Peter J B Sabatini, Tracy L Stockley, Lillian L Siu. Genome Med 2020
108
16

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Ittai B Muller, Adrianus J De Langen, Richard J Honeywell, Elisa Giovannetti, Godefridus J Peters. Expert Rev Anticancer Ther 2016
23
16

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, Benjamin J Solomon, Gregory J Riely, Myung-Ju Ahn, Caicun Zhou, S Martin Shreeve, Paulina Selaru, Anna Polli,[...]. J Clin Oncol 2015
415
16

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
Giulio Genovese, Anna K Kähler, Robert E Handsaker, Johan Lindberg, Samuel A Rose, Samuel F Bakhoum, Kimberly Chambert, Eran Mick, Benjamin M Neale, Menachem Fromer,[...]. N Engl J Med 2014
16


Age-related clonal hematopoiesis associated with adverse outcomes.
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick, Alisa Manning, Peter V Grauman, Brenton G Mar, R Coleman Lindsley, Craig H Mermel, Noel Burtt, Alejandro Chavez,[...]. N Engl J Med 2014
16

Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.
Louise Carter, Dominic G Rothwell, Barbara Mesquita, Christopher Smowton, Hui Sun Leong, Fabiola Fernandez-Gutierrez, Yaoyong Li, Deborah J Burt, Jenny Antonello, Christopher J Morrow,[...]. Nat Med 2017
175
16

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.
C Allison Stewart, Carl M Gay, Yuanxin Xi, Santhosh Sivajothi, V Sivakamasundari, Junya Fujimoto, Mohan Bolisetty, Patrice M Hartsfield, Veerakumar Balasubramaniyan, Milind D Chalishazar,[...]. Nat Cancer 2020
49
16

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.
Marzia Del Re, Elena Arrigoni, Giuliana Restante, Antonio Passaro, Eleonora Rofi, Stefania Crucitta, Filippo De Marinis, Antonello Di Paolo, Romano Danesi. Stem Cells 2018
18
16

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Sanjay Popat, Tony Mok, James Chih-Hsin Yang, Yi-Long Wu, Juliane Lungershausen, Uz Stammberger, Ingolf Griebsch, Tiago Fonseca, Luis Paz-Ares. Lung Cancer 2014
39
16

Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications.
Hiu Ting Chan, Yoon Ming Chin, Yusuke Nakamura, Siew-Kee Low. Cancers (Basel) 2020
20
16

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C Lee, Justin F Gainor, Adam S Crystal, Pierre-Yves Michellys, Mark M Awad, Noriko Yanagitani, Sungjoon Kim,[...]. Cancer Discov 2014
537
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.